Entity

Time filter

Source Type

Bellinzona, Switzerland

Monticelli S.,Institute for Research in Biomedicine
Seminars in Immunology | Year: 2013

Understanding how T cells generate productive and long-lasting responses, and how these mechanisms are dysregulated in autoimmune and inflammatory disorders is crucial for prevention and treatment of these diseases. MicroRNAs (miRNAs) are short noncoding RNA species able to suppress gene expression post-transcriptionally. Hundreds of different miRNAs are produced in a cell starting from longer precursors. While the role of miRNAs has been clearly established in the regulation of the differentiation, proliferation and effector functions of a variety of immune cells, here I will focus specifically on miRNAs known to be involved in regulating the biology of CD4 T helper lymphocytes. © 2013 Elsevier Ltd. Source


Pinto D.,Institute for Research in Biomedicine
Blood | Year: 2013

Plasma cells (PCs) are terminally differentiated cells of the B-cell lineage that secrete antibodies at a high rate and are thought to lack the expression of the B-cell receptor (BCR). Here, we report that human IgA and IgM, unlike IgG, PCs express a membrane functional BCR associated with the Igα/Igβ heterodimer. BCR cross-linking on IgA and IgM PCs led to Ca(2+) mobilization and extracellular signal-regulated kinase 1/2 and AKT phosphorylation and impacted survival of IgA PCs. These findings demonstrate a significant difference between human IgG, IgM, and IgA PCs and suggest that the IgA PC repertoire may be modulated by specific antigens with implications for the regulation of the mucosal immune system. Source


Patent
Institute For Research In Biomedicine | Date: 2015-12-17

The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.


Patent
Institute For Research In Biomedicine | Date: 2013-04-16

The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.


Patent
Institute For Research In Biomedicine | Date: 2015-07-31

The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

Discover hidden collaborations